Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H25N5O4 |
Molecular Weight | 447.4864 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=NC=NC(OC3=CC=C(CC(=O)NC4=CN(N=C4)C(C)C)C=C3)=C2C=C1OC
InChI
InChIKey=TWYCZJMOEMMCGC-UHFFFAOYSA-N
InChI=1S/C24H25N5O4/c1-15(2)29-13-17(12-27-29)28-23(30)9-16-5-7-18(8-6-16)33-24-19-10-21(31-3)22(32-4)11-20(19)25-14-26-24/h5-8,10-15H,9H2,1-4H3,(H,28,30)
Molecular Formula | C24H25N5O4 |
Molecular Weight | 447.4864 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22153662
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22153662
AZD2932 is an oral inhibitor of VEGFR-2 and PDGFR tyrosine kinases, which was developed by AstraZeneca as a potential anti-cancer medicine. The drug was tested in vivo in preclinical model of mice bearing C6 rat glial tumors and AZD2932 demonstrated good potency: growth of Calu-6 tumor was inhibited by
81% and 72% at 50 and 12.5 mg/kg b.i.d. and LoVo tumors by 67% at 50 mg/kg b.i.d.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35968 Gene ID: 3791.0 Gene Symbol: KDR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22153662 |
8.0 nM [IC50] | ||
Target ID: P09619 Gene ID: 5159.0 Gene Symbol: PDGFRB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22153662 |
4.0 nM [IC50] | ||
Target ID: P16234 Gene ID: 5156.0 Gene Symbol: PDGFRA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22153662 |
2.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22153662
Preclinical model: AZD2932 is given orally twice a day at a dose 12.5 or 50 mg/kg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:11:18 GMT 2023
by
admin
on
Sat Dec 16 12:11:18 GMT 2023
|
Record UNII |
SJ9PP5S9IM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
883986-34-3
Created by
admin on Sat Dec 16 12:11:18 GMT 2023 , Edited by admin on Sat Dec 16 12:11:18 GMT 2023
|
PRIMARY | |||
|
11517980
Created by
admin on Sat Dec 16 12:11:18 GMT 2023 , Edited by admin on Sat Dec 16 12:11:18 GMT 2023
|
PRIMARY | |||
|
SJ9PP5S9IM
Created by
admin on Sat Dec 16 12:11:18 GMT 2023 , Edited by admin on Sat Dec 16 12:11:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |